Screener
Capricor Therapeutics CAPR Interest Expense, Nonoperating
Interest Expense, Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Capricor Therapeutics’s 10-K, filed March 17, 2026.
- Filed
- Mar 17, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-029580
| Line item | Years ended December 31, 2025 | Years ended December 31, 2024 |
|---|---|---|
| OTHER INCOME (EXPENSE) | ||
| Other income | 45,421 | 7,471 |
| Investment income | 6,257,607 | 2,202,990 |
| Interest expense | (3,045,725) | — |
| Loss on disposal of fixed assets | (157,519) | (112,805) |
| TOTAL OTHER INCOME (EXPENSE) | 3,099,784 | 2,097,656 |
| LOSS BEFORE INCOME TAXES | (105,042,346) | (40,465,586) |
| (Provision for) benefit from income taxes | (1,600) | (1,600) |
ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Capricor Therapeutics's interest expense, nonoperating?
- Capricor Therapeutics (CAPR) reported interest expense, nonoperating of $761.43K in Q4 2025.
- What does interest expense, nonoperating mean?
- This captures interest costs incurred on debt obligations that are not directly related to the company's core operating activities. It reflects the cost of capital and the financial burden of the company's debt structure. High levels of nonoperating interest expense can indicate significant leverage and potential liquidity risks for a development-stage firm.
Ask your AI about Capricor Therapeutics's interest expense, nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude